Pure Global
NCT05940532

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

A Single-arm Phase 2 Study of Sugemalimab and Chemotherapy as Induction Therapy in Unresectable and Stage III Non-small Cell Lung Cancer (NSCLC)
Hunan Cancer Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention
Sugemalimab and Chemotherapy
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hunan Cancer Hospital
Location
Changsha, China
Timeline & enrollment
Phase
Phase 2
Start date
Jun 14, 2023
End date
Dec 01, 2026
Enrollment
41 participants
Primary outcome

ORR

Summary

The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and
 safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team
 (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05940532
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05940532 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Cancer Hospital and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 41 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.